Search our team at AdventHealth Research Institute
-
NCT05514717
A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants with Advanced/Recurrent Solid Tumors that Express HER2
This study is not currently enrolling.Associated Conditions: Metastatic Solid TumorsResearch Area: Clinical Cancer ResearchResearch Location: Celebration, FloridaThe purpose of the study is to: During the Dose Escalation part, find the most tolerated dose of the Study Drug that may provide potential benefit. During the Enrichment and Expansion parts, further...
-
External Evaluation Plan: User Evaluation of the Next Generation CardioLab EP Recording System with the Prucka 3 Digital EP Amplifier
This study is not currently enrolling.Research Area: Heart, Lung and Vascular ResearchResearch Location: Celebration, FloridaThe current CardioLab system is cleared by the FDA for use on patients of all ages when a physician determines that a patient would benefit from an electrophysiology procedure. CardioLab can be used...
-
NCT06253130
EIK1003-001 (IMP1734-101): A first-in-human, Phase 1/2, open-label, multi-center, dose escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors
This study is not currently enrolling.Research Area: Clinical Cancer ResearchResearch Location: Celebration, FloridaThe study treatment is IMP1734, which is an experimental drug which means that regulatory authorities have allowed the study to be tested in this clinical trial for its potential to treat cancers in...
-
NCT06026410
KO-2806-001: Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors
This study is not currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Clinical Cancer ResearchResearch Location: Celebration, FloridaThe purposes of this study are to:
• Determine the highest tolerable dose of KO-2806 given orally (by mouth) in combination with cabozantinib.
• Determine whether KO-2806 has an antitumor effect... -
NCT05176483
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (STELLAR-002)
This study is not currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Clinical Cancer ResearchResearch Location: Celebration, FloridaYou are being asked to take part in a clinical research study called STELLAR-002 because you have been diagnosed with cancer or your cancer has worsened since your last treatment. If you join this...